molnupiravir

IUPAC name:

[(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate

CAS No.

2349386-89-4

Molecular Weight:

329.31g.mol−1

Molecular Formula:

C13H19N3O7

Granule:

Available-Ready to fill

Mechanism Of Action:

Molnupiravir is hydrolyzed in vivo to N4-hydroxycytidine, which is phosphorylated in tissue to the active 5’-triphosphate form, and incorporated into the genome of new versions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe. A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.

Indication:

N4-hydroxycytidine and its prodrug are being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.

It is approved in the UK for reducing the risk of hospitalization and death in mild to moderate COVID-19 cases for patients at increased risk of severe disease (eg. with obesity, diabetes mellitus, heart disease, or are over 60 years old).

In the US, it is authorized for emergency use for the treatment of high-risk adults with mild to moderate COVID-19.

information

Category: Covid 19

January 21, 2024

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1

DABRAFENIB MESYLATE

Oncology

Cas No: 1195768-06-9

Mechanism Of Action: Dabrafenib is recognized as a competitive and highly selective inhibitor of BRAF. Its mechanism of action involves binding to the ATP pocket

Abemaciclib

Oncology

Cas No: 1231929-97-7

Mechanism Of Action: Abemaciclib demonstrates high selectivity in inhibiting CDK4 and CDK6 with potent activity in the low nanomolar range. By inhibiting the phosphorylation of

Sacubitril-Valsartan

Cardiovascular

Cas No: 936623-90-4

Mechanism Of Action: Sacubitril/valsartan is a medication that exerts its effects through the dual inhibition of neprilysin, an enzyme responsible for degrading certain peptides, and

Roxadustat

Anti-Anemic

Cas No: 808118-40-3

Mechanism Of Action: Anemia is a common complication of chronic kidney disease that can be caused by reduced production of renal erythropoietin (EPO), functional iron